{"id":1302,"date":"2024-09-03T12:28:51","date_gmt":"2024-09-03T12:28:51","guid":{"rendered":"http:\/\/www.caltagmedsystems.co.uk\/information\/?p=1302"},"modified":"2025-04-28T13:45:25","modified_gmt":"2025-04-28T13:45:25","slug":"mhc-class-i-tetramers","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/mhc-class-i-tetramers\/","title":{"rendered":"MHC Class I Tetramers"},"content":{"rendered":"\n

T cell receptors (TCRs) expressed on the surface of T cells specifically recognise and bind to complexes of major histocompatibility complex (MHC) molecules and peptide fragments expressed on the surface of antigen-presenting cells. CD8+ T cells, also called cytotoxic T lymphocytes (CTLs), recognise complexes of MHC class I molecules and peptides. CTLs directly kill target cells including virus-infected and cancer cells.<\/p>\n\n\n\n

Preparation of MHC Class I Tetramer Reagents<\/h3>\n\n\n\n

MHC class I tetramer reagents are generated primarily using the method developed by Altman et al., who demonstrated that tetramers of MHC class I\/peptide complexes could be used as probes for the detection and quantitation of antigen-specific CTL (Science 1996, 274: 94-96).<\/p>\n\n\n\n

E. coli-expressed recombinant MHC class I heavy chain and \u03b22-microglobulin (\u03b22m) are folded in the presence of a peptide antigen to generate a soluble monomeric MHC class I\/peptide complex (monomer). The monomer is then biotinylated by the biotin ligase enzyme, BirA, at a lysine residue present in the biotinylation sequence that has been added to the C-terminus of the MHC class I heavy chain. The biotinylated monomer is purified by column chromatography. Purified biotinylated monomers are tetramerised by mixing with a fluorescently labelled streptavidin to make MHC tetramer reagents.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Greater Specificity: The patented \u03b13 mutation* – Exclusive to MBL Tetramers<\/h3>\n\n\n\n

The human leukocyte antigen (HLA) system is the name of the major histocompatibility complex in humans. CD8 molecules are known to assist binding of HLA to CTL in vivo<\/em> and thus HLA molecules have binding sites for CD8 molecules.  Bodinier et al. reported that introducing a mutation (A245V) in the HLA class I heavy chain \u03b13 domain minimized unwanted binding to CD8 molecules and dramatically improved specificity (Nat. Med. 2000, 6: 707). MBL has incorporated the patented mutation of the \u03b13 domain in their HLA class I tetramers and is the only manufacturer of MHC multimers with this technology to enhance specificity for the antigen-specific T cell receptor.<\/p>\n\n\n\n

*Only human and macaque HLA Class I Tetramers contain the alpha 3 mutation.<\/p>\n\n\n\n

\"tetramer_a3\"<\/a><\/figure>\n\n\n\n

Class I Available Alleles – Stock Tetramers<\/h3>\n\n\n\n

Human:<\/h4>\n\n\n\n
HLA-A*01:01<\/a><\/td>HLA-B*07:02<\/a><\/td>HLA-C*03:03<\/a><\/td><\/tr>
HLA-A*02:01<\/a><\/td>HLA-B*08:01<\/a><\/td><\/td><\/tr>
HLA-A*03:01<\/a><\/td>HLA-B*15:01<\/a><\/td><\/td><\/tr>
HLA-A*11:01<\/a><\/td>HLA-B*35:01<\/a><\/td><\/td><\/tr>
HLA-A*24:02<\/a><\/td><\/td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Mouse:<\/h4>\n\n\n\n
H-2 Kb<\/a><\/td>H-2 Db<\/a><\/td>H-2 Ld<\/a><\/td><\/tr>
<\/td>H-2 Dd<\/a><\/td> <\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Rhesus Macaque:<\/h4>\n\n\n\n
Mamu-A*90120-5<\/a><\/td><\/td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Chicken:<\/h4>\n\n\n\n
BF2*1201<\/a><\/td>BF2*1501<\/a><\/td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n\n\n\n

Information provided by MBL.<\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of MBL <\/a>products in the UK and Ireland. If you have any questions about these products, please contact us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

T cell receptors (TCRs) expressed on the surface of T cells specifically recognise and bind to complexes of major histocompatibility complex (MHC) molecules and peptide fragments expressed on the surface of antigen-presenting cells. CD8+ T cells, also called cytotoxic T<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,15],"tags":[928,67,802,105],"class_list":["post-1302","post","type-post","status-publish","format-standard","hentry","category-general-information","category-tetramer","tag-class-i","tag-mbl-international","tag-mhc-tetramers","tag-tetramers"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/1302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=1302"}],"version-history":[{"count":20,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/1302\/revisions"}],"predecessor-version":[{"id":12197,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/1302\/revisions\/12197"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=1302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=1302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=1302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}